Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF

There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yılmaz, Sedat, Tekgöz, Emre, Çınar, Muhammet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267750/
https://www.ncbi.nlm.nih.gov/pubmed/30071938
http://dx.doi.org/10.5152/eurjrheum.2018.17183
Descripción
Sumario:There is no established treatment protocol for amyloid-A (AA) amyloidosis secondary to Familial Mediterranean Fever (FMF). Recently, we reported the efficacy of tocilizumab in 11 amyloidosis cases associated with FMF. In 2 patients of 11, we discontinued the tocilizumab administeration owing to the normalization of amyloidosis-related symptoms, but proteinuria re-occurred eventually. Fortunately, the patients responded to tocilizumab re-treatment. This led us to conclude that physicians should not stop the treatment, even in patients with normalized proteinuria levels.

Ejemplares similares